Trial Profile
Efficacy and Safety of an Initial Regimen Raltegravir (RAL) + Lamivudine/Abacavir Fixed-Dose Combination (3TC/ABC FDC) for 48 Weeks in ART-naive, HIV/TB Co-Infected Adult Subjects Receiving Rifabutin-containing, 1-line Anti-TB Therapy.
Status:
Recruiting
Phase of Trial:
Phase IV
Latest Information Update: 11 May 2022
Price :
$35
*
At a glance
- Drugs Raltegravir (Primary) ; Lamivudine/abacavir
- Indications HIV-1 infections
- Focus Therapeutic Use
- 05 May 2011 Actual initiation date (Oct 2010) added as reported by ClinicalTrials.gov.
- 05 May 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.
- 06 Feb 2010 New trial record